Pajjiż: Stati Uniti
Lingwa: Ingliż
Sors: NLM (National Library of Medicine)
PROPAFENONE HYDROCHLORIDE (UNII: 33XCH0HOCD) (PROPAFENONE - UNII:68IQX3T69U)
Avera McKennan Hospital
PROPAFENONE HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE 225 mg
PRESCRIPTION DRUG
Abbreviated New Drug Application
PROPAFENONE HCL- PROPAFENONE HYDROCHLORIDE TABLET, FILM COATED AVERA MCKENNAN HOSPITAL ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE PROPAFENONE HYDROCHLORIDE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR PROPAFENONE HYDROCHLORIDE TABLETS. PROPAFENONE HYDROCHLORIDE TABLETS FOR ORAL USE INITIAL U.S. APPROVAL: 1989 WARNING: MORTALITY _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ AN INCREASED RATE OF DEATH OR REVERSED CARDIAC ARREST RATE WAS SEEN IN PATIENTS TREATED WITH ENCAINIDE OR FLECAINIDE (CLASS IC ANTIARRHYTHMICS) COMPARED WITH THAT SEEN IN PATIENTS ASSIGNED TO PLACEBO. AT PRESENT IT IS PRUDENT TO CONSIDER ANY IC ANTIARRHYTHMIC TO HAVE A SIGNIFICANT RISK OF PROVOKING PROARRHYTHMIC EVENTS IN PATIENTS WITH STRUCTURAL HEART DISEASE. GIVEN THE LACK OF ANY EVIDENCE THAT THESE DRUGS IMPROVE SURVIVAL, ANTIARRHYTHMIC AGENTS SHOULD GENERALLY BE AVOIDED IN PATIENTS WITH NONLIFE-THREATENING VENTRICULAR ARRHYTHMIAS, EVEN IF THE PATIENTS ARE EXPERIENCING UNPLEASANT, BUT NOT LIFE-THREATENING, SYMPTOMS OR SIGNS. RECENT MAJOR CHANGES Contraindications (4) 3/2013 Warnings and Precautions, Unmasking Brugada Syndrome (5.2) 3/2013 INDICATIONS AND USAGE Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients who do not have structural heart disease. (1) treat documented life-threatening ventricular arrhythmias. (1) USAGE CONSIDERATIONS: Use in patients with permanent atrial fibrillation or with atrial flutter or PSVT has not been evaluated. Do not use to control ventricular rate during atrial fibrillation. (1) In patients with atrial fibrillation and atrial flutter, use pro Aqra d-dokument sħiħ